AcuCort held its Capital Markets Day in Stockholm on 13 October. During the morning, the company presented its path forward, with a focus on its international expansion in Europe and the US. A recording of the Capital Markets Day is now available to watch. The presentations are in Swedish.
During the Capital Markets Day, CEO Jonas Jönmark, Business Development Director Anna Chérouvrier Hansson and Strategic Alliance Manager Carl Frisk provided further insight into Zeqmelit®, AcuCort's international partnerships, experience from the Nordic market and plans for future expansion.
In Europe, AcuCort has entered into a commercial agreement with Glenmark Pharmaceuticals covering six markets, with launches planned for 2027. In parallel, the company continues its preparations for a New Drug Application (NDA) for Zeqmelit® in the US.
Watch the recording of AcuCort's Capital Markets Day here:
https://youtu.be/nsS0GzikvFY
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.